Cargando…

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations

Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaiser, Christina, Knight, Ann, Nordström, Dan, Pettersson, Tom, Fransson, Jonas, Florin-Robertsson, Ebba, Pilström, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264859/
https://www.ncbi.nlm.nih.gov/pubmed/21881988
http://dx.doi.org/10.1007/s00296-011-2096-3
_version_ 1782222015626739712
author Kaiser, Christina
Knight, Ann
Nordström, Dan
Pettersson, Tom
Fransson, Jonas
Florin-Robertsson, Ebba
Pilström, Björn
author_facet Kaiser, Christina
Knight, Ann
Nordström, Dan
Pettersson, Tom
Fransson, Jonas
Florin-Robertsson, Ebba
Pilström, Björn
author_sort Kaiser, Christina
collection PubMed
description Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of anakinra is to competitively inhibit the local inflammatory effects of IL-1. Kineret is generally safe and well tolerated and the only major treatment-related side effects that appear are skin reactions at the injection site. Due to the relatively short half-life of anakinra, daily injection of the drug is required. This, in combination with the comparably high rates of injection-site reactions (ISRs) associated with the drug, can become a problem for the patient. The present review summarises published data concerning ISRs associated with Kineret and provides some explanations as to their cause. The objective is also to present some clinical experiences of how the ISRs can be managed.
format Online
Article
Text
id pubmed-3264859
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-32648592012-02-03 Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations Kaiser, Christina Knight, Ann Nordström, Dan Pettersson, Tom Fransson, Jonas Florin-Robertsson, Ebba Pilström, Björn Rheumatol Int Review Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of anakinra is to competitively inhibit the local inflammatory effects of IL-1. Kineret is generally safe and well tolerated and the only major treatment-related side effects that appear are skin reactions at the injection site. Due to the relatively short half-life of anakinra, daily injection of the drug is required. This, in combination with the comparably high rates of injection-site reactions (ISRs) associated with the drug, can become a problem for the patient. The present review summarises published data concerning ISRs associated with Kineret and provides some explanations as to their cause. The objective is also to present some clinical experiences of how the ISRs can be managed. Springer-Verlag 2011-09-01 2012 /pmc/articles/PMC3264859/ /pubmed/21881988 http://dx.doi.org/10.1007/s00296-011-2096-3 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Kaiser, Christina
Knight, Ann
Nordström, Dan
Pettersson, Tom
Fransson, Jonas
Florin-Robertsson, Ebba
Pilström, Björn
Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
title Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
title_full Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
title_fullStr Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
title_full_unstemmed Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
title_short Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
title_sort injection-site reactions upon kineret (anakinra) administration: experiences and explanations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264859/
https://www.ncbi.nlm.nih.gov/pubmed/21881988
http://dx.doi.org/10.1007/s00296-011-2096-3
work_keys_str_mv AT kaiserchristina injectionsitereactionsuponkineretanakinraadministrationexperiencesandexplanations
AT knightann injectionsitereactionsuponkineretanakinraadministrationexperiencesandexplanations
AT nordstromdan injectionsitereactionsuponkineretanakinraadministrationexperiencesandexplanations
AT petterssontom injectionsitereactionsuponkineretanakinraadministrationexperiencesandexplanations
AT franssonjonas injectionsitereactionsuponkineretanakinraadministrationexperiencesandexplanations
AT florinrobertssonebba injectionsitereactionsuponkineretanakinraadministrationexperiencesandexplanations
AT pilstrombjorn injectionsitereactionsuponkineretanakinraadministrationexperiencesandexplanations